Axel Dignass 1, Ayesha Akbar 2, Ailsa Hart 2, Sreedhar Subramanian 3, Gilles Bommelaer 4, Daniel C Baumgart 5, Jean-Charles Grimaud 6, Guillaume Cadiot 7, Richard Makins 8, Syed Hoque 9, Guillaume Bouguen 10, Bruno Bonaz 11 , J Crohns Colitis. 2016 Jul;10(7):812-20.
Safety and efficacy of granulocyte/monocyte apheresis in steroid-dependent active ulcerative colitis with insufficient response or intolerance to immunosuppressants and/or biologics (ART trial): 12-week interim results.
At Week 12, Adacolumn provided significant clinical benefit in a large cohort of steroid-dependent ulcerative colitis patients with previous failure to immunosuppressant and/or biologic treatment, with a favourable safety profile. These results are consistent with previous studies and support Adacolumn use in this difficult-to-treat patient subgroup.
Contact UsFor more informationContact Us